The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

[1]  Guido Marcucci,et al.  Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. , 2008, Cancer research.

[2]  M. Lübbert,et al.  Current status of epigenetic treatment in myelodysplastic syndromes , 2008, Annals of Hematology.

[3]  H. Blair,et al.  PINCH-1 Regulates the ERK-Bim Pathway and Contributes to Apoptosis Resistance in Cancer Cells* , 2008, Journal of Biological Chemistry.

[4]  J. Issa,et al.  Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine , 2008, Leukemia & lymphoma.

[5]  G. Basso,et al.  Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation* , 2007, Journal of Biological Chemistry.

[6]  G. Mufti,et al.  CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine , 2007, Leukemia.

[7]  R. Claus,et al.  Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. , 2007, Blood.

[8]  M. Lübbert,et al.  Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. , 2007, Leukemia research.

[9]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[10]  S. Sanche,et al.  Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. , 2007, Experimental hematology.

[11]  R. Larson,et al.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Z. Estrov,et al.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. , 2006, Blood.

[13]  H. Stopper,et al.  Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. , 2006, Cancer research.

[14]  Peter A. Jones,et al.  Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.

[15]  John K Field,et al.  Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Momparler.  Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). , 2005, Seminars in oncology.

[17]  L. Shih,et al.  Dlk1 in normal and abnormal hematopoiesis , 2005, Leukemia.

[18]  M. Minden,et al.  Decitabine in acute myeloid leukemia. , 2005, Seminars in hematology.

[19]  V. Marquez,et al.  Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. , 2005, Biochemical Pharmacology.

[20]  M. Goggins,et al.  Epigenetic Down-Regulation of CDKN1C/p57KIP2 in Pancreatic Ductal Neoplasms Identified by Gene Expression Profiling , 2005, Clinical Cancer Research.

[21]  S. Wageningen,et al.  ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells , 2005, Leukemia.

[22]  M. Bernstein,et al.  Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia , 2005, Anti-cancer drugs.

[23]  B. Dörken,et al.  Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms , 2005, Leukemia.

[24]  James B. Mitchell,et al.  Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. , 2004, Cancer cell.

[25]  Gangning Liang,et al.  Preferential response of cancer cells to zebularine. , 2004, Cancer cell.

[26]  A. Lasa,et al.  MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias , 2004, Leukemia.

[27]  Peter A. Jones,et al.  Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells , 2004, Molecular and Cellular Biology.

[28]  David A Jones,et al.  Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. , 2004, Molecular pharmacology.

[29]  G. Rivard,et al.  Cell cycle effects and cellular pharmacology of 5-AZA-2′-deoxycytidine , 2004, Cancer Chemotherapy and Pharmacology.

[30]  Peter A. Jones,et al.  Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. , 2002, Cancer research.

[31]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[32]  Matty P. Weijenberg,et al.  A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer , 2002, Nature Genetics.

[33]  Peter A. Jones,et al.  Advances in Brief Analysis of Gene Induction in Human Fibroblasts and Bladder Cancer Cells Exposed to the Methylation Inhibitor 5-Aza-2-deoxycytidine 1 , 2002 .

[34]  E. Lander,et al.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.

[35]  S. Groshen,et al.  Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. , 2001, Journal of the National Cancer Institute.

[36]  John C Rockett,et al.  Arrays of DNA-binding sites , 2001, Genome Biology.

[37]  Cheng Li,et al.  Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application , 2001, Genome Biology.

[38]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  N. C. Price,et al.  Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. , 1999, Journal of molecular biology.

[40]  A. Feinberg,et al.  Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia , 1996, Nature Genetics.

[41]  N. Kamada,et al.  Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. , 1993, Blood.

[42]  N. Kamada,et al.  Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. , 1991, Blood.

[43]  R. Momparler,et al.  Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus. , 1974, Cancer research.